Correlation Between Abcellera Biologics and Allovir

Can any of the company-specific risk be diversified away by investing in both Abcellera Biologics and Allovir at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Abcellera Biologics and Allovir into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Abcellera Biologics and Allovir, you can compare the effects of market volatilities on Abcellera Biologics and Allovir and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Abcellera Biologics with a short position of Allovir. Check out your portfolio center. Please also check ongoing floating volatility patterns of Abcellera Biologics and Allovir.

Diversification Opportunities for Abcellera Biologics and Allovir

-0.51

Correlation Coefficient

Abcellera Biologics  Allovir

Excellent diversification

The 3 months correlation between Abcellera and Allovir is -0.51. Overlapping area represents the amount of risk that can be diversified away by holding Abcellera Biologics and Allovir in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allovir and Abcellera Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Abcellera Biologics are associated (or correlated) with Allovir. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allovir has no effect on the direction of Abcellera Biologics i.e., Abcellera Biologics and Allovir go up and down completely randomly.

Pair Corralation between Abcellera Biologics and Allovir

Given the investment horizon of 90 days Abcellera Biologics is expected to generate 0.54 times more return on investment than Allovir. However, Abcellera Biologics is 1.85 times less risky than Allovir. It trades about 0.03 of its potential returns per unit of risk. Allovir is currently generating about -0.07 per unit of risk. If you would invest  273.00  in Abcellera Biologics on September 17, 2024 and sell it today you would earn a total of  8.00  from holding Abcellera Biologics or generate 2.93% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Abcellera Biologics  vs.  Allovir

Abcellera Biologics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Abcellera Biologics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite quite weak fundamental indicators, Abcellera Biologics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Allovir

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Allovir has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Abcellera Biologics and Allovir

The main advantage of trading using opposite Abcellera Biologics and Allovir positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Abcellera Biologics position performs unexpectedly, Allovir can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will offset losses from the drop in Allovir's long position.

The idea behind Abcellera Biologics and Allovir pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.